Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660890 · ClinicalTrials.gov registry record · Phase 1
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT04660890 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT04660890, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
Interventions
- DRUG Moxifloxacin
- DRUG ALXN2050
- DRUG ALXN2050-matching Placebo
- DRUG Moxifloxacin-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-12-12 |
| Est. Completion | 2021-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04660890
The ClinicalTrials.gov registry entry for NCT04660890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT04660890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04660890 about?
NCT04660890 is a clinical study titled "A Study of the Cardiac Effects of ALXN2050 in Healthy Adults". This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
What is the current status of trial NCT04660890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2020-12-12. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT04660890?
The interventions under investigation include: Moxifloxacin (DRUG), ALXN2050 (DRUG), ALXN2050-matching Placebo (DRUG), Moxifloxacin-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT04660890?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.